Ibuprofen is associated with initiation or exacerbation of ulcerative colitis. As ibuprofen selectively inhibited fatty acid oxidation in the liver or caused mitochondrial damage in intestinal cells, its effect on substrate oxidation by isolated colonocytes of man and rat was examined. Ibuprofen dose dependently (2.0-7.5 mmol/l) and selectively inhibited 14C02 production from labelled n-butyrate in colonocytes from the proximal and distal human colon (n=12, p=<0.001). Glucose oxidation was either unaltered or increased. Because short chain fatty acid oxidation is the main source of acetyl-CoA for long chain fatty acid synthesis, the inhibition of prostaglandin synthesis by ibuprofen in the colonic mucosa could also occur at this level. Because the concentrations of ibuprofen that can be attained in the human colon are not known, conclusions drawn from current dosages are tentative. The inhibition of fatty acid oxidation by ibuprofen may be biochemically implicated in the initiation and exacerbation of ulcerative colitis, manifestation of which would depend on the ibuprofen concentrations reached in the colon. (Gut 1995; 36: 55-59) 
Non steroidal anti-inflammatory drugs (NSAIDs) can have deleterious effects on the intestinal mucosa. In the colon, these drugs can produce colitis de novo or cause exacerbation of quiescent ulcerative colitis.'-3 NSAIDs produce permeability changes in the colonic mucosa independent of colitis,4 or cause colonic bleeding5 with or without stricturing and diaphragm formation.6 7 Even though the inhibition of cyclo-oxygenases and therefore prostaglandin production has been invoked as a causative factor of damage,' 3 there also seems a lack of correlation between reduced mucosal synthesis of prostaglandins and the degree of mucosal injury. 8 The epithelial barrier of the colonic mucosa in health is maintained by nutrition from the lumen through n-butyrate9-11 derived from bacterial fermentation of starches. Fatty acid oxidation of n-butyrate in (6) performed were subject to Student's paired 6-43 (0.68) (6) t test. The 0.05 probability level was taken to 500 (054) (6) indicate a significant difference in observa- (Fig 1) , which reflected a 79% reduction of fatty acid oxidation, while reduction of glucose at that concentration of drug was 60% from 0.60 (0.04) to 0.24 (0.06) ,umol/min/g (dry weight). Ketogenesis and lactogenesis were reduced in parallel with the reduction of 14C02 (Table I) . 5-ASA led to a slight reduction in both butyrate and glucose oxidation, a reduction that at 7.5 mmol/l was significantly different from that produced by ibuprofen (p=<0 01 for glucose and p=<O 001 for n-butyrate).
Human colonocytes were only exposed to drug concentrations of 2.00 and 7.5 mmol/l with both glucose and n-butyrate, each drug exposure comprising cells from the same batch of cell isolates. Unlike findings with rat colonocytes, 5-ASA did not reduce either n-butyrate or glucose oxidation in the proximal or distal human colon, but ibuprofen at 7.5 mmol/l selectively diminished fatty acid oxidation (Figs 2 and 3) and ketogenesis (Table II) . It is noteworthy that ibuprofen stimulated glucose oxidation, particularly in the distal colon (Fig 2) . Lactogenesis was significantly reduced in the presence of 5-ASA (Table II) The reduction of butyrate oxidation by 79% by ibuprofen in human colonocytes reflects an overall decrease of 55% of cell energy as butyrate normally supplies 70% of cellular oxidation9-1' in colonocytes. Because both lipogenesis12 and efficient absorption are dependent upon butyrate-oxidation, any impairment of fatty acid oxidation can explain changes of membrane permeability4 observed with ibuprofen. The mechanism proposed for ibuprofen damage in the colon is in line with the evolution of ulcerative colitis that is related to impairment of fatty acid oxidation.14-6 A reduction in fatty acid oxidation suggests a mechanism whereby ibuprofen can both exacerbate and cause ulcerative colitis.
Ibuprofen reduces the growth of colonic polyps and tumours.39 40 This effect may depend upon the inhibition of butyrate oxidation because n-butyrate normally promotes the growth of colonic tumour cells to a more differentiated form.41 The proposed explanation would relate to metabolic changes in mitochondria and cytoplasm of colonocytes rather than nucleic acids, implying that neoplastic lesions may be diminished by change in fatty acid oxidation but not eradicated. This is in keeping with the effects of ibuprofen noted in the formation of experimental colon cancer. 39 The observations now made with ibuprofen on fatty acid oxidation cannot be extended to other NSAIDs until these have been individually investigated. Nevertheless changes in fatty acid oxidation with ibuprofen may explain a number of clinical and experimental observations with regard to colonic mucosal disease, especially ulcerative colitis. The dose dependent metabolic changes observed in the colonocytes indicate that continued use of ibuprofen is possible in colonic disease but at a lower dosage range.
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